Comments on: I told you so: Eat your Bioheart out http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/ News About Tech, Money and Innovation Mon, 23 Nov 2009 13:10:15 +0000 http://wordpress.org/?v=2.8.5 hourly 1 By: Three yards and a cloud of dust: Bioheart makes it across the IPO goal line, but with little to show for its struggles » VentureBeat http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-795860 Three yards and a cloud of dust: Bioheart makes it across the IPO goal line, but with little to show for its struggles » VentureBeat Wed, 20 Feb 2008 04:22:59 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-795860 [...] on MyoCell expires next year, and you still have what looks like a looming disaster. (I took a second whack at the company in October when its offering seemed to be on the brink of [...] [...] on MyoCell expires next year, and you still have what looks like a looming disaster. (I took a second whack at the company in October when its offering seemed to be on the brink of [...]

]]> By: Three yards and a cloud of dust: Bioheart makes it across the IPO goal line, but with little to show for its struggles » VentureBeat http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-795861 Three yards and a cloud of dust: Bioheart makes it across the IPO goal line, but with little to show for its struggles » VentureBeat Wed, 20 Feb 2008 04:22:59 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-795861 [...] on MyoCell expires next year, and you still have what looks like a looming disaster. (I took a second whack at the company in October when its offering seemed to be on the brink of [...] [...] on MyoCell expires next year, and you still have what looks like a looming disaster. (I took a second whack at the company in October when its offering seemed to be on the brink of [...]

]]> By: VentureBeat » Life sciences briefing: Thursday, Jan. 17, 2007 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-739398 VentureBeat » Life sciences briefing: Thursday, Jan. 17, 2007 Thu, 17 Jan 2008 21:07:02 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-739398 [...] woes started last October, when it abruptly slashed its offering price and fired its underwriters. The company’s IPO has lingered on life support ever since. We gave readers some good reasons [...] [...] woes started last October, when it abruptly slashed its offering price and fired its underwriters. The company’s IPO has lingered on life support ever since. We gave readers some good reasons [...]

]]> By: VentureBeat » EnteroMedics and its risky obesity device, the latest victims of the IPO haircut http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-633404 VentureBeat » EnteroMedics and its risky obesity device, the latest victims of the IPO haircut Wed, 14 Nov 2007 21:38:13 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-633404 [...] terms, and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...] [...] terms, and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Nov. 14, 2007 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-633306 VentureBeat » Life sciences briefing: Wednesday, Nov. 14, 2007 Wed, 14 Nov 2007 21:07:32 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-633306 [...] terms, and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...] [...] terms, and hasn’t yet managed to get its offering off the ground. (See our recent coverage here and here.) Like EnteroMedics, Bioheart is pushing ahead with a risky, largely unproven technology [...]

]]> By: VentureBeat » IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-599860 VentureBeat » IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings Sun, 28 Oct 2007 22:59:00 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-599860 [...] The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with [...] [...] The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with [...]

]]> By: VentureBeat » IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-599846 VentureBeat » IPO roundup: Bioheart, Merrion Pharma in limbo; Reliant vs. Reliant road shows; upcoming offerings Sun, 28 Oct 2007 22:58:59 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-599846 [...] The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with [...] [...] The week of Oct. 22 has come and gone, and there’s no sign of the scheduled — and already battered — IPO of Bioheart, the Florida company that hopes to treat damaged hearts with [...]

]]> By: Mr. Gunn http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-594596 Mr. Gunn Wed, 24 Oct 2007 22:46:06 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-594596 Interestingly, I just saw two new articles in Pubmed on <a href="http://synthesis.williamgunn.org/2007/10/22/whats-interesting-in-pubmed-this-week-stem-cells/" rel="nofollow">Adult Stem Cells and cardiac fibrosis</a>. Personally, I think the rush to clinical trials in this area before much of the basic science has been worked out has been a mistake. How many clinical trials do we need to have that show a barely-significant increase in ejection fraction or diastolic volume before people start ignoring them? (Disclosure of my own: I work in a lab that does research on adult stem cells, but I have no financial interest beyond my paycheck and I haven't been involved with the heart stuff.) Interestingly, I just saw two new articles in Pubmed on Adult Stem Cells and cardiac fibrosis. Personally, I think the rush to clinical trials in this area before much of the basic science has been worked out has been a mistake. How many clinical trials do we need to have that show a barely-significant increase in ejection fraction or diastolic volume before people start ignoring them?

(Disclosure of my own: I work in a lab that does research on adult stem cells, but I have no financial interest beyond my paycheck and I haven’t been involved with the heart stuff.)

]]> By: VentureBeat » Life sciences briefing: Wednesday, Oct. 24, 2007 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-594190 VentureBeat » Life sciences briefing: Wednesday, Oct. 24, 2007 Wed, 24 Oct 2007 19:06:27 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-594190 [...] fared badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...] [...] fared badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...]

]]> By: VentureBeat » Life sciences briefing: Wednesday, Oct. 24, 2007 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-594204 VentureBeat » Life sciences briefing: Wednesday, Oct. 24, 2007 Wed, 24 Oct 2007 19:06:27 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-594204 [...] fared badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...] [...] fared badly, with shares now down 16 percent. Next up is Bioheart, which we’ve covered here and here, and whose star-crossed IPO is still scheduled for this [...]

]]> By: David P. Hamilton http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-592524 David P. Hamilton Tue, 23 Oct 2007 19:29:03 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-592524 Peggy: Thanks for the clarification, although as the item noted, that list of investors came from VentureWire. If a correction is necessary, you might want to notify them as well. I would only add that when investment firms choose to structure themselves in complex and hard-to-decipher ways -- witness, for instance, how the Ascent Group decribes itself <a href="http://www.ascentcompanies.com/content/the-ascent-group-of-companies.html" rel="nofollow">here</a> -- that it's very easy for journalists and others to misunderstand them. Of course, I couldn't help also noticing that a Peggy Farley is named as a co-founder of both Ascent Medical Technology funds (see her bio <a href="http://www.ascentcompanies.com/content/biographies.html" rel="nofollow">here</a>). She is also listed in Bioheart's S-1 as the beneficial owner of 494,410 Bioheart shares, whose maximum value just plummeted to $4.0 million from $7.9 million. Would you happen to be that same Ms. Farley? If so, I certainly can't blame you for not liking the item, although I think our readers would benefit if you could disclose your personal financial interest when commenting. (FYI, I own no individual-company shares whatsoever; my investments are limited to broad-based mutual funds, none of which invest in specific commercial sectors such as the life sciences.) In any event, if you have other specific issues to raise about the item, I'm more than happy to address them, either here or by e-mail. Peggy: Thanks for the clarification, although as the item noted, that list of investors came from VentureWire. If a correction is necessary, you might want to notify them as well. I would only add that when investment firms choose to structure themselves in complex and hard-to-decipher ways — witness, for instance, how the Ascent Group decribes itself here — that it’s very easy for journalists and others to misunderstand them.

Of course, I couldn’t help also noticing that a Peggy Farley is named as a co-founder of both Ascent Medical Technology funds (see her bio here). She is also listed in Bioheart’s S-1 as the beneficial owner of 494,410 Bioheart shares, whose maximum value just plummeted to $4.0 million from $7.9 million.

Would you happen to be that same Ms. Farley? If so, I certainly can’t blame you for not liking the item, although I think our readers would benefit if you could disclose your personal financial interest when commenting. (FYI, I own no individual-company shares whatsoever; my investments are limited to broad-based mutual funds, none of which invest in specific commercial sectors such as the life sciences.)

In any event, if you have other specific issues to raise about the item, I’m more than happy to address them, either here or by e-mail.

]]> By: Peggy Farley http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-592482 Peggy Farley Tue, 23 Oct 2007 18:55:09 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-592482 It is Ascent Medical Technology Fund I and II that invested in Bioheart, not Ascent/Meredith. Also, I consider your article poor journalism--very yellow journalism. It is Ascent Medical Technology Fund I and II that invested in Bioheart, not Ascent/Meredith. Also, I consider your article poor journalism–very yellow journalism.

]]> By: VentureBeat » Dan Marino’s hail mary pass: Bioheart http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/comment-page-1/#comment-575976 VentureBeat » Dan Marino’s hail mary pass: Bioheart Fri, 12 Oct 2007 19:07:49 +0000 http://venturebeat.com/2007/10/12/i-told-you-so-eat-your-bioheart-out/#comment-575976 [...] Bioheart, an oddball “adult” stem-cell company based in Sunrise, Fla., has slashed its IPO price range — essentially halving the company’s expected market value. David Hamilton, over at VentureBeat Life Sciences, says: “I told you so: Eat your Bioheart out.” [...] [...] Bioheart, an oddball “adult” stem-cell company based in Sunrise, Fla., has slashed its IPO price range — essentially halving the company’s expected market value. David Hamilton, over at VentureBeat Life Sciences, says: “I told you so: Eat your Bioheart out.” [...]

]]>